Screener
Spyre Therapeutics, Inc. SYRE Business Segments — Compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Compensation | $11,443 | $6,991 |
| Stock-based compensation (1) | 12,806 | 8,859 |
| Research and development, excluding compensation and stock-based compensation (2) (3) | 46,893 | 33,551 |
| Other segment items (4) (5) | (2,137) | (4,628) |
| Segment net loss | $69,005 | $44,773 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s business segments — compensation?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — compensation of $11.44M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s business segments — compensation changed year-over-year?
- Spyre Therapeutics, Inc.'s business segments — compensation increased by 63.7% year-over-year, from $6.99M to $11.44M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — compensation?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s business segments — compensation has grown at a 10.5% compound annual growth rate (CAGR), from $25.78M to $34.8M.
- What does business segments — compensation mean?
- Represents the total cash-based salary, wages, and benefits paid to employees within the primary business segment. This metric reflects the core human capital investment required to sustain operational and research activities.
Ask your AI about Spyre Therapeutics, Inc.'s business segments — compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude